Latest Cost Savings News

Noble Helium has postponed its Western margin drilling program and appointed Dennis Donald as Non-Executive Chairman, while actively pursuing refinancing and cost-saving measures to sustain its flagship North Rukwa Project.

Hawsons Iron Limited has completed key process optimisation activities, including promising dry grinding tests that suggest significant energy and cost savings. The company is finalising a Project Study and attracting new investor interest following recent industry engagements.

Carbonxt Group advances commissioning of its Kentucky activated carbon plant while securing $2.5 million in fresh capital and reporting strong sales growth and cost savings ahead of FY26.

Propell Holdings reports Q3 FY25 cash outflows alongside a strategic shift with a new ‘Low Doc’ credit model and confirms its upcoming ASX delisting.

Elixinol Wellness reported a 13.7% year-on-year revenue increase in Q1 FY25, despite a softer quarter compared to record Q4, with ecommerce momentum and strategic initiatives setting the stage for margin recovery and growth in H2.

Vintage Energy reported a dip in quarterly sales and production but achieved cost savings and secured a key permit renewal, positioning itself for a production uplift program despite recent flooding delays.

MedAdvisor Solutions reported a challenging third quarter with steep revenue declines, driven by delayed program launches and US sales underperformance, but is executing a strategic overhaul and cost-cutting measures to position for a rebound and 15% revenue growth in FY26.

MedAdvisor Limited reports a steep decline in 3Q FY25 revenue, driven by US market challenges, while accelerating cost-cutting and reaffirming full-year guidance.

QPM Energy reports a substantial 61% upgrade in Moranbah Gas Project reserves to 435PJ, successfully integrates Moranbah Power Station operations, and begins overhaul of Townsville Power Station, navigating weather disruptions and contract renewals.

Atomos Limited announces a key leadership transition with COO Peter Barber appointed CEO, succeeding co-founder Jeromy Young who will remain on the board as a Non-Executive Director.

Omni Bridgeway reports robust investment performance for FY25, highlighted by record proceeds and a landmark Fund 9 transaction that strengthens its balance sheet and strategic position.

Argent BioPharma reports significant operational savings through manufacturing outsourcing, encouraging Phase IIb results for CimetrA®, and key regulatory approvals for cannabinoid therapies in Germany.